Endo Health to pay $192.7M in gov't settlement

February 22, 2014 by The Associated Press

Endo Health will pay almost $193 million to resolve claims that it improperly marketed the shingles treatment Lidoderm for unapproved uses like treating lower back pain.

The Malvern, Pennsylvania, drugmaker will pay $171.9 million in civil false claims settlements largely to the U.S. government, with $34.2 million from that total going to 47 states and the District of Columbia. Endo also agreed to pay $20.8 million as part of a deferred prosecution agreement.

U.S. prosecutors said Friday that Endo Health Solutions Inc. marketed the for unapproved uses between 2002 and 2006.

Endo said it was pleased to resolve the issue, and it has programs in place to help it comply with the agreements. The had already set aside $194 million to cover settlement costs.

Doctors can prescribe medicines for any use, but drug makers cannot promote them in any way that is not approved by the U.S. Food and Drug Administration.

Explore further: Pfizer to pay $491M to resolve drug marketing case (Update)

Related Stories

Pfizer to pay $491M to resolve drug marketing case (Update)

July 30, 2013
The U.S. Justice Department said Tuesday that drugmaker Pfizer Inc. will pay almost $491 million to resolve an investigation into illegal marketing of the organ transplant drug Rapamune by a company Pfizer later acquired.

NJ drugmaker faces civil, criminal fines over drug

March 5, 2013
(AP)—A New Jersey-based generic drug maker has agreed to pay $45 million to resolve criminal and civil liability charges for improperly marketing its weight-gain drug to frail seniors.

Merck will pay $950M to settle Vioxx investigation

November 22, 2011
(AP) -- The Department of Justice said Tuesday that drugmaker Merck will pay $950 million to resolve investigations into its marketing of the painkiller Vioxx.

Amgen to pay record $762 mn fine over anemia drug (Update)

December 18, 2012
US pharmaceutical giant Amgen has pleaded guilty to illegally introducing a mislabeled drug for treating anemia onto the market and will pay a record $762 million fine, officials said Wednesday.

J&J to pay $2.2B to settle marketing allegations (Update)

November 4, 2013
Johnson & Johnson and its subsidiaries have agreed to pay over $2.2 billion to resolve criminal and civil allegations that the company promoted powerful psychiatric drugs for unapproved uses in children, seniors and disabled ...

FDA denies request to block generic painkiller

May 10, 2013
In a surprise move, federal health regulators have denied a request by Endo Health Solutions to block generic versions of its painkiller Opana ER, which the company argued can be more easily abused than its branded product.

Recommended for you

Vaccinating against psoriasis, allergies and Alzheimer's a possibility, research shows

October 23, 2017
Research from the Universities of Dundee and Oxford has shown how combining the tetanus vaccine with a viral particle that normally affects cucumbers can be used to treat psoriasis and allergies, and may even protect against ...

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.